

(efgartigimod alfa and hyaluronidase-qvfc) Subcutaneous Injection 180 mg/mL and 2000 U/mL | 200 mg/mL and 2000 U/mL (efgartigimod alfa-fcab) Intravenous Injection 400 mg/20 mL vial

PHARMACY VS MEDICAL BENEFIT GUIDE

This information is current as of the date of publication but is subject to change.

argenx supports optionality for patients by providing 2 routes of administration - VYVGART[®] (efgartigimod alfa-fcab) for intravenous use via a vial and VYVGART Hytrulo[®] (efgartigimod alfa and hyaluronidase-qvfc) for subcutaneous injection via a vial that is administered by a healthcare provider (HCP) or a prefilled syringe that may be self-injected.

Considering all available coverage options will help you and your patient identify the therapy that best meets your patient's needs. Review the information below to help you understand how different types of health plan benefits and other factors generally influence access to prescribed therapy.

Understanding pharmacy benefit vs medical benefit PHARMACY C Medical benefit Pharmacy benefit Self-administered injections or oral Intravenous infusions or injections Drug formulation treatment¹ administered by an HCP² Provider acquires the product from Patient receives the product directly Acquisition specialty distributor or specialty from the specialty pharmacy pharmacy Patient's home or other appropriate HCP office, infusion center, outpatient Treatment location^a setting hospital facility, home infusion ^aAssuming compliance with instructions for use Determined by pharmacy benefit Insurance manager or health plan's drug Determined by medical policy coverage² formulary and policy Medicare Part B, Part B with Medigap Medicare Medicare Part D³ coverage, or Part C/Medicare Advantage coverage coverage⁴ Co-pay for office or hospital visit; Patient cost² Co-pay or co-insurance for drug co-insurance for drug Specialty pharmacy manages billing HCP/site of care has option to buy and **Billing**² and dispensing; claims processing bill^b; claims processing occurs after occurs in real time treatment is administered Insurance Prescription and medical benefit information may be on separate cards; ensure you information collect both. Some Medicare patients may have a supplemental insurance card

^bInvolves the HCP/office purchasing specialty drugs and managing an internal stock of specialized treatments. These medications can then be allocated to patients and administered onsite by HCPs within the practice or an alternative site of care such as an infusion center, etc. This is an alternative option to using a specialty pharmacy or other collaborator. The buy-and-bill process involves the HCP purchasing, storing, and then administering the product to a patient.²





(efgartigimod alfa and hyaluronidase-qvfc) Subcutaneous Injection 180 mg/mL and 2000 U/mL | 200 mg/mL and 2000 U/mL

(efgartigimod alfa-fcab) Intravenous Injection 400 mg/20 mL vial

argenx has a dedicated field team to provide education support to HCPs and their offices.



Territory Business Manager



My VYVGART Path
Patient Support Team



Field Reimbursement Manager

Territory Business Managers are your primary point of contact for argenx products

- · Provide education and resources on argenx products and services
- · Connect HCPs and offices with an argenx field team member as needed



Enroll your patients in My VYVGART Path for a patient-specific benefits verification that provides ways patients can access prescribed therapy

My VYVGART Path Patient Support Team can help with the following:

- · Assist with benefits investigations, prior authorizations, and financial assistance
- · Identify appropriate site of care for HCP-administered products
- Ensure prescription for prefilled syringe is delivered to contracted in-network specialty pharmacy
- Provide disease education and training to enrolled patients
- Provide personalized support through nurse case managers

Field Reimbursement Managers can provide education and support access and reimbursement for argenx products

- · Provide general access and reimbursement education to HCPs and offices
- Provide case-specific support to assist in getting patients on treatment^c
- Educate on My VYVGART Path resources

[Business card plastic sleeve]

Please see full Prescribing Information for VYVGART in pocket or at VYVGARTHCP.com/Pl and full Prescribing Information for VYVGART HYTRULO in pocket or at VYVGARTHCP.com/Hytrulo-Pl.

 $^{\rm c}\mbox{Case-specific support}$ is limited to patients enrolled in My VYVGART Path.

References: 1. Vogenberg FR, Santilli J, Eng K. Bend the curve: a new era for the management of specialty pharmaceuticals. Access Market Intelligence. Accessed November 14, 2024. https://accessmarketintell.com/wp-content/uploads/2016/08/Bend-the-curve-final.pdf 2. NAMAPA. The importance of a thorough benefits investigation to help navigate medical vs pharmacy benefit. Accessed November 14, 2024. https://www.namapa.org/medical-vs-pharmacy-benefit 3. CMS. Fact sheet: Medicare Prescription Payment Plan. August 2023. Accessed November 14, 2024. https://www.cms.gov/files/document/medicare-prescriptionpayment-plan-fact-sheet.pdf 4. Medicare.gov. Learn how Medigap works. Accessed November 14, 2024. https://www.medicare.gov/health-drug-plans/medigap/ basics/how-medigap-works

For US audiences only. VYVGART and VYVGART Hytrulo are registered trademarks of argenx. © 2025 argenx US-VYV-24-00501 V1 04/2025. All Rights Reserved.

